Index RUT
P/E -
EPS (ttm) -2.73
Insider Own 15.01%
Shs Outstand 42.00M
Perf Week -1.22%
Market Cap 1.81B
Forward P/E 23.57
EPS next Y 1.82
Insider Trans -1.07%
Shs Float 35.71M
Perf Month -14.06%
Income -104.94M
PEG -
EPS next Q -0.39
Inst Own 101.08%
Short Float 23.27%
Perf Quarter -10.18%
Sales 233.67M
P/S 7.73
EPS this Y 61.77%
Inst Trans -11.02%
Short Ratio 11.29
Perf Half Y -3.72%
Book/sh 8.15
P/B 5.27
EPS next Y 255.34%
ROA -24.69%
Short Interest 8.31M
Perf Year 10.95%
Cash/sh 9.71
P/C 4.43
EPS next 5Y -
ROE -33.98%
52W Range 20.08 - 57.28
Perf YTD -22.39%
Dividend Est. -
P/FCF -
EPS past 5Y -66.60%
ROI -25.32%
52W High -24.98%
Beta 0.86
Dividend TTM -
Quick Ratio 5.54
Sales past 5Y 172.29%
Gross Margin 92.99%
52W Low 113.97%
ATR (14) 2.24
Dividend Ex-Date -
Current Ratio 5.57
EPS Y/Y TTM 42.86%
Oper. Margin -46.72%
RSI (14) 38.96
Volatility 2.77% 2.97%
Employees 323
Debt/Eq 0.21
Sales Y/Y TTM 449.03%
Profit Margin -44.91%
Recom 1.25
Target Price 70.86
Option/Short Yes / Yes
LT Debt/Eq 0.21
EPS Q/Q 36.93%
Payout -
Rel Volume 0.48
Prev Close 43.19
Sales Surprise 8.15%
EPS Surprise 12.32%
Sales Q/Q 183.68%
Earnings May 01 AMC
Avg Volume 736.15K
Price 42.97
SMA20 -7.16%
SMA50 -10.17%
SMA200 -1.74%
Trades
Volume 350,700
Change -0.51%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Initiated
Goldman
Neutral
$19
Jul-18-23 Initiated
William Blair
Outperform
$44
May-18-23 Initiated
Guggenheim
Buy
Aug-01-22 Initiated
Barclays
Overweight
$40
Dec-21-21 Initiated
H.C. Wainwright
Buy
$40
Nov-23-21 Initiated
Oppenheimer
Outperform
$55
Nov-10-20 Initiated
Raymond James
Strong Buy
$39
Nov-10-20 Initiated
Ladenburg Thalmann
Buy
$42
Nov-10-20 Initiated
Jefferies
Buy
$35
Nov-10-20 Initiated
BofA Securities
Buy
$33
May-14-25 09:45AM
May-08-25 05:00PM
May-05-25 06:04PM
May-02-25 03:17AM
May-01-25 09:37PM
05:35PM
Loading…
05:35PM
04:05PM
Apr-30-25 10:17AM
09:55AM
Apr-25-25 10:00AM
Apr-24-25 05:00PM
11:00AM
Apr-23-25 01:41PM
Apr-22-25 11:19AM
08:31AM
04:05PM
Loading…
Apr-21-25 04:05PM
Mar-28-25 03:59PM
Mar-20-25 09:05AM
Mar-12-25 09:49PM
04:12PM
Mar-06-25 05:00PM
Feb-26-25 02:13AM
(Thomson Reuters StreetEvents)
02:05AM
Feb-25-25 08:40AM
07:00AM
01:31AM
Feb-20-25 05:00PM
Jan-30-25 05:00PM
Jan-20-25 03:31PM
Jan-14-25 09:35AM
08:30AM
Loading…
Jan-13-25 08:30AM
Dec-26-24 10:30AM
(Investor's Business Daily)
Dec-04-24 09:55AM
Nov-18-24 09:55AM
Nov-14-24 02:15AM
Nov-13-24 05:30PM
04:05PM
08:30AM
Nov-07-24 10:00AM
Nov-06-24 04:30PM
Nov-05-24 08:30AM
Oct-30-24 06:39AM
Oct-17-24 08:30AM
Oct-09-24 05:56PM
Sep-25-24 05:00PM
Aug-28-24 05:00PM
Aug-08-24 09:56PM
06:05PM
04:05PM
Jul-29-24 04:30PM
May-29-24 05:00PM
May-09-24 05:00PM
(GlobeNewswire) -8.86%
+8.70%
12:48PM
11:06AM
03:49AM
May-08-24 08:58PM
05:40PM
04:05PM
May-06-24 09:55AM
May-01-24 05:00PM
Apr-23-24 08:30AM
Apr-09-24 07:35AM
Apr-08-24 09:55AM
Apr-04-24 11:33AM
Apr-01-24 12:00PM
Mar-06-24 09:55AM
Mar-05-24 04:30PM
08:30AM
Mar-01-24 12:07AM
Feb-29-24 04:37PM
Feb-28-24 12:00PM
09:58AM
Feb-27-24 11:13PM
(Thomson Reuters StreetEvents) +18.28%
06:34AM
06:00AM
Feb-22-24 08:00AM
Feb-20-24 05:00PM
Jan-31-24 05:00PM
Jan-30-24 04:06AM
Jan-21-24 07:01AM
Dec-21-23 03:32PM
(Investor's Business Daily)
Dec-11-23 08:00AM
Dec-01-23 11:04PM
Nov-12-23 12:15PM
Nov-09-23 04:05PM
(GlobeNewswire) -5.86%
+12.20%
Nov-01-23 06:35PM
Sep-06-23 08:00AM
Aug-30-23 04:30PM
Aug-28-23 10:22AM
Aug-24-23 09:00AM
Aug-10-23 04:05PM
Aug-03-23 02:14PM
Aug-01-23 10:30PM
(GlobeNewswire) -16.99%
-5.53%
Jul-31-23 04:29PM
Jul-25-23 07:00AM
Jul-20-23 02:04PM
Jul-19-23 08:34PM
10:13AM
Jun-12-23 08:30AM
Jun-05-23 08:30AM
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Azamian Bobak R. President/CEO and Board Chair Mar 24 '25 Sale 50.00 6,000 300,000 824,106 Mar 26 04:47 PM Azamian Bobak R. Officer Mar 24 '25 Proposed Sale 50.00 6,000 300,000 Mar 24 05:35 PM Mottiwala Aziz Chief Commercial Officer Mar 18 '25 Sale 46.29 3,643 168,634 71,979 Mar 20 09:49 PM Mottiwala Aziz Chief Commercial Officer Mar 20 '25 Sale 50.11 3,365 168,620 65,057 Mar 20 09:49 PM Mottiwala Aziz Chief Commercial Officer Mar 19 '25 Sale 47.40 3,557 168,602 68,422 Mar 20 09:49 PM Neervannan Seshadri Chief Operating Officer Mar 20 '25 Sale 50.11 2,435 122,018 79,682 Mar 20 09:49 PM Neervannan Seshadri Chief Operating Officer Mar 18 '25 Sale 46.29 2,605 120,585 84,660 Mar 20 09:49 PM Neervannan Seshadri Chief Operating Officer Mar 19 '25 Sale 47.40 2,543 120,538 82,117 Mar 20 09:49 PM Wahl Bryan General Counsel Mar 18 '25 Sale 46.29 3,341 154,655 58,057 Mar 20 09:49 PM Wahl Bryan General Counsel Mar 19 '25 Sale 47.40 3,261 154,571 54,796 Mar 20 09:49 PM Wahl Bryan General Counsel Mar 20 '25 Sale 50.11 3,084 154,539 51,712 Mar 20 09:49 PM Whitfield Dianne C. Chief Human Resources Officer Mar 18 '25 Sale 46.29 2,315 107,161 50,751 Mar 20 09:48 PM Whitfield Dianne C. Chief Human Resources Officer Mar 20 '25 Sale 50.11 2,137 107,085 46,355 Mar 20 09:48 PM Whitfield Dianne C. Chief Human Resources Officer Mar 19 '25 Sale 47.40 2,259 107,077 48,492 Mar 20 09:48 PM Azamian Bobak R. President/CEO and Board Chair Mar 20 '25 Sale 50.11 8,534 427,639 53,635 Mar 20 09:48 PM Azamian Bobak R. President/CEO and Board Chair Mar 19 '25 Sale 47.40 8,551 405,317 62,169 Mar 20 09:48 PM Azamian Bobak R. President/CEO and Board Chair Mar 18 '25 Sale 46.29 7,131 330,094 70,720 Mar 20 09:48 PM Farrow Jeffrey S See Remarks Mar 19 '25 Sale 47.40 1,254 59,440 23,617 Mar 20 09:48 PM Farrow Jeffrey S See Remarks Mar 18 '25 Sale 46.29 1,284 59,436 24,871 Mar 20 09:48 PM Farrow Jeffrey S See Remarks Mar 20 '25 Sale 50.11 1,186 59,430 22,431 Mar 20 09:48 PM Whitfield Dianne C. Officer Mar 20 '25 Proposed Sale 50.11 2,137 107,093 Mar 20 04:35 PM Farrow Jeffrey S Officer Mar 20 '25 Proposed Sale 50.11 1,186 59,435 Mar 20 04:30 PM Mottiwala Aziz Officer Mar 20 '25 Proposed Sale 50.11 3,365 168,632 Mar 20 04:29 PM Wahl Bryan Officer Mar 20 '25 Proposed Sale 50.11 3,084 154,550 Mar 20 04:21 PM Neervannan Seshadri Officer Mar 20 '25 Proposed Sale 50.11 2,435 122,026 Mar 20 04:18 PM Azamian Bobak R. Officer Mar 20 '25 Proposed Sale 50.11 8,534 427,669 Mar 20 04:11 PM Neervannan Seshadri Officer Mar 19 '25 Proposed Sale 47.40 2,543 120,536 Mar 19 03:27 PM Wahl Bryan Officer Mar 19 '25 Proposed Sale 47.40 3,261 154,569 Mar 19 03:24 PM Azamian Bobak R. Officer Mar 19 '25 Proposed Sale 47.40 8,551 405,311 Mar 19 03:23 PM Whitfield Dianne C. Officer Mar 19 '25 Proposed Sale 47.40 2,259 107,075 Mar 19 03:22 PM Farrow Jeffrey S Officer Mar 19 '25 Proposed Sale 47.40 1,254 59,439 Mar 19 03:12 PM Mottiwala Aziz Officer Mar 19 '25 Proposed Sale 47.40 3,557 168,599 Mar 19 03:12 PM Neervannan Seshadri Officer Mar 18 '25 Proposed Sale 46.28 2,605 120,571 Mar 18 04:31 PM Wahl Bryan Officer Mar 18 '25 Proposed Sale 46.28 3,341 154,637 Mar 18 04:26 PM Mottiwala Aziz Officer Mar 18 '25 Proposed Sale 46.28 3,643 168,614 Mar 18 04:26 PM Whitfield Dianne C. Officer Mar 18 '25 Proposed Sale 46.28 2,315 107,149 Mar 18 04:20 PM Azamian Bobak R. Officer Mar 18 '25 Proposed Sale 46.28 7,131 330,055 Mar 18 04:15 PM Farrow Jeffrey S Officer Mar 18 '25 Proposed Sale 46.28 1,284 59,429 Mar 18 04:12 PM Goldberg Andrew D. Director Mar 07 '25 Option Exercise 12.89 7,000 90,230 13,350 Mar 11 04:01 PM LINK WILLIAM J PHD Director Aug 12 '24 Sale 26.08 35,000 912,961 0 Aug 14 04:34 PM FLYING L PARTNERS XI LLC Director Aug 12 '24 Proposed Sale 26.85 35,000 939,750 Aug 12 04:25 PM Farrow Jeffrey S See Remarks Jun 18 '24 Sale 27.47 10,445 286,924 18,136 Jun 20 04:26 PM